In the Middletown program some 10,000 children under the age of 18 received oral poliovirus vaccine (Sabin strains) in two doses: the first given in January 1961, consisting of monovalent vaccine containing Type I poliovirus, and the second six weeks later, in March 1961, a bivalent vaccine containing polioviruses types II and III. The study is the culmination of a six-year program concerned with oral poliovirus vaccines in which the Yale Poliomyelitis Study Unit has been engaged since the Sabin attenuated poliovirus strains first became available to us in 1955.t Of the several trials of oral vaccination which this Unit has conducted, this has been the largest we have attempted and one which has benefited from both our own previous experiences and those of others whose reports have been accumulating rapidly during the past two or three years.
By and large, the general objective of the Yale Poliomyelitis Study Unit has been to observe and study carefully what happens to a population when some of its members are artificially infected (vaccinated) with attenuated poliovirus strains and others are intimately exposed to individuals so infected. In other words, we have regarded these trials in large part as a setting for work in experimental epidemiology, with the rare opportunity to do freely in man what previously, in the study of other diseases, has been possible only in populations of animals or birds. Thus we have had as a major objective the accumulation of information and knowledge with regard to the ecology of infection in man caused by attenuated poliomyelitis viruses.
In most of our previous trials we have not attempted to assume responsibility for immunizing a given population as a public health measure. This, we believe, is more properly the function of a city or state public health department or agency. The role of a university epidemiological department in this situation is rather a more scientific one, although the Yale studies have not all been of a theoretical nature. They have had their practical aspects, for obviously our study unit has been concerned with the search for and the development of new and improved methods of immunization against poliomyelitis. Nearly all previous trials have required some teamwork, in which the participation and cooperation of various agencies or individuals, many of them health officers, has been extensive.
During the past five years there has been no dearth of trials and studies by others on both the broader public health aspects and the experimental aspects of oral vaccination against poliomyelitis. These are not only exemplified in the investigations of Dr. Sabin Foteword I PAUL utensils used in the cottages were sterilized. Immune responses to oral vaccination were measured, and surveys were conducted to determine the capacity of the attenuated viruses to spread within the institution to intimate and less intimate associates among both juvenile and adult groups.' Also we made one of the earliest studies on genetic markers of poliovirus strains recovered from vaccinees as a means of detecting possible indications of reversion to a more virulent form. In addition, we encountered early in 1956 a previously undescribed phenomenon, namely that of "local alimentary tract immunity," which has played such an important part in subsequent decisions as to what the oral vaccine might be expected to accomplish over and above its capacity to confer serological immunity on individual vaccinees. This phenomenon came out particularly when oral poliovirus vaccine was given to two groups of individuals: a) those whose antibodies had been derived from the Salk-type vaccine, and b) those whose antibodies had been acquired naturally from inapparent infection with wild polioviruses. The first group proved easy to infect with homotypic attenuated polioviruses; the second, however, was much more resistant to what was obviously a reinfection with homotypic poliovirus. This phenomenon of local (alimentary) resistance, which deserves much more work, has been ascribed to an inability of polioviruses to gain much of a foothold in an alimentary tract which previously has been the site of homotypic viral multiplication.
On the basis of the existence of this phenomenon of intestinal resistance, the claim has been made that following mass use of oral vaccine, not only are individuals immunized, but a kind of community-wide intestinal immunity can be established, thus making it possible to break the chain of transmission and eliminate polioviruses from sizeable communities.
Subsequent to the Southbury studies we ventured outside the confines of an institution and began a series of village trials to enable us to study effects of the oral vaccine when given under natural conditions in an open community. Communities with sanitation of a relatively low order were first chosen: an American-Indian village in southern Arizona,"'14 and a village in Costa Rica, C.A.' 1 In the latter study we had our first opportunity to deal with children who had not previously received the Salk-type vaccine. Also, because the Costa Rican Ministry of Health was starting a campaign using an oral poliovirus vaccine composed of the Lederle strains, we used the Lederle vaccine for the first and only time instead of that made from the Sabin strains of attenuated polioviruses. This is not the time nor place to record and discuss many of the interesting aspects of the studies in these two (Arizona and Costa Rican) trials. We were confronted in both with a population of young children, some of whom were highly immune, and we were able to observe that a high level of immunity in the local community curtailed the spread of attenuated poliovirus infection. In both villages we encountered the difficult problem posed by the presence of competing enteroviruses and the various degrees of interference with vaccine "takes" which some of them cause. We were also able, in both villages, to observe the manner in which local flies pick up enteroviruses during a vaccine trial."'6 These insects are capable of spreading virulent polioviruses and presumably are also capable of spreading attenuated polioviruses, thus serving as immunizing agents, if you will.
Continuing somewhat along this line we had, in 1960, the opportunity of carrying out an extensive trial in some 350 preschool children in New
Haven.'7 The medical profession in this city, the Health Department, and the Visiting Nurse Association were sympathetic and helpful, and the population chosen for the trial reacted favorably to the idea of live poliovirus vaccine. It thus proved possible (and indeed feasible) to carry out this urban trial with meticulous care, as a kind of clinical investigation under university auspices assisted by community health agencies.
For some years it has been apparent that not only are preschool children less accessible for the administration of the Salk-type vaccine than are children of school age, but biologically they do not respond as well to such inactivated antigen in so far as the development and maintenance of antibodies is concerned. In the New Haven trial we were particularly concerned with the 0-5 year age group of low socio-economic status. This hard-toreach preschool group has some epidemiological significance, since in any population young children are the most readily infected and are also the chief spreaders of polioviruses. Also, it is in young children that most of the paralytic cases now occur, for the age distribution of poliomyelitis in the United States has returned to what amounts to the old-fashioned "infantile paralysis." This was true of the 1959 poliomyelitis epidemic in New Haven, and many similar recent epidemics in the United States. Thus there were important reasons for determining how completely and effectively one could reach and immunize a preschool group. Papers II-VI and VIII in the Middletown series should be viewed in this light.
Another problem of practical importance considered in the New Haven Study was that of testing the comparative merits of three different dosage schedules: a) three monovalent vaccines given in three doses one month apart in the order type I, type III, type II; b) monovalent type I vaccine, followed six weeks later by bivalent types II and III; and c) trivalent vaccine given twice, six weeks apart. All three of these schedules proved to be almost equally (and highly) effective in producing antibodies to the three types, with the antibody levels showing only slight decline after one year. Although there was little to choose among the different schedules on immunological grounds, certainly there is a practical advantage in using two doses instead of three.
In testing the pre-and post-vaccinal immune status of the children in the New Haven trial, we used for the first time in the field, a micro-method for the determination of neutralizing antibodies, devised by Drs. R. Green and E. M. Opton of this department."8 This method proved to have an enormous advantage when it came to bleeding young infants in the home.
Also, community environmental studies were carried out by examining for poliovirus, sewage samples from some of the housing projects where children participating in the vaccine trial lived. This was done to determine how long the attenuated poliovirus strains remained in a community of this type and size. Such information was correlated with data on individual excretion rates as determined by testing weekly rectal swabs from each vaccinee.
Another important recent project has dealt with post-oral vaccinal viremia in young children. Following some preliminary observations in the New Haven trial, we were fortunate to be able to continue this study at the New York Foundling Hospital* in children who had not received Salk-type vaccine. The objective was to see if viremia could be detected in "triple-negative" subjects after the ingestion of each of the three Sabin strains of oral poliovirus vaccine. Previous studies by others had indicated that the Lederle type I and the Sabin type II strains did give rise now and again to viremia and that such viruses were more readily recovered postvaccinally from the blood of individuals lacking antibodies to all three types. In brief, the results of these incomplete studies have been clear-cut and informative. Of 22 triple-negative children, age 5 to 18 months, 21 were found to have become infected after ingestion of Sabin type I vaccine, but virus was not detected in the blood of any child, nor was "bound" viremia (virus + antibody) detected in any of the 66 specimens tested.
In considerable contrast were the results with type II. Twenty-two triple-negative children were fed type II vaccine, and all became infected. "Free" viremia was detected in 11 (50 per cent) and "bound" viremia in an additional eight ( viremia in vaccinees is not entirely clear. Presumably, in view of the field data on safety, it is an expression of rather extensive extraneural multiplication of a strain which nevertheless has an extremely low neurotropic capacity.
The Middletown trial and comparable trials by other groups. With the background of the experiences described above, the Yale Poliomyelitis Study Unit undertook the Middletown trial, essentially to test the feasability and effectiveness of a city-wide mass vaccination project. Prior to the initiation of the study, there had been a number of so-called mass vaccination trials in which, within a relatively few days, oral vaccine was administered on a city-wide scale to large numbers of preschool and school-aged children. In connection with these trials, some of the reasons for the use of oral poliovirus vaccine on a simultaneous mass basis have been discussed. They are numerous. It is administratively advantageous to give the vaccine to those age groups designated as more susceptible, in a short campaign lasting but a few days rather than to administer it to all age groups over a period of weeks, months, or years. It is easier to reach more individuals who need vaccination in this way. Enthusiasm can be stirred by a community campaign urging people to take the vaccine, whereas such enthusiasm may not exist under other circumstances. There are also epidemiological reasons for the quick flooding, as it were, of the population of a given city with one type of attenuated poliovirus at a time. By this means it is possible to avoid problems of interference between types of polioviruses; indeed, if two or three poliovirus types are being administered sporadically to various groups of the same population, a certain amount of interference among the three types may be expected to occur. This might result in vaccination failures in some instances.
The part to be played by the health officer in the many administrative problems connected with any mass program of oral poliovirus vaccine administration is an extremely important one. Later, after the mass campaign has been completed, it is necessary to maintain the level of immunization within a given population by vaccinating infants born into the community; the practicing physician assumes a position of first importance in this second phase.
Of the other city-wide trials conducted in this country in 1960 during the inter-epidemic period, Dr. Sabin's trial in Cincinnati has been a most important one.'9 This involved a large population group of some 300,000 people, most of whom were under the age of 18. Monovalent vaccine was used; the first dose (type I) was given in the late spring of 1960 (May-June) and the others (types III and II) sequentially in the fall so that the campaign of mass vaccination actually lasted six months. The Cincinnati study included a careful system of surveillance and extensive laboratory work on a sample of the vaccinated population. It was a trial conducted largely under university auspices with the cooperation of the local health department.
The Rochester trial, in which the Sabin strains were used, was essentially under municipal health department auspices.' The objective here was somewhat different in that the program did not call for such extensive laboratory tests as were carried out in the Cincinnati study; essentially it was a practical demonstration of the health department's role in the task of vaccinating a population with this new form of immunizing agent.
Other city-wide trials carried out in 1960 in the United States, using the Lederle strains, include one in Miami, Florida, and various trials in Minnesota.
Consequently it was with a background of some experience gained both by ourselves and by others that the Middletown oral vaccine trial was embarked upon early in 1961. How nearly it met its objectives and what was learned can be found in the following reports.
Too much emphasis cannot be laid upon the teamwork required in investigations of this kind. The selection of names of various members of the Yale Poliomyelitis Study Unit and other assistants as authors of the papers which follow was far from easy. A great many people did a great deal of work in this project; some of them are not given credit so that it would be more realistic to say that these papers are by the Yale Poliomyelitis Study Unit, the Middletown Department of Health, and many other friends.
